F bevacizumab, , with chemotherapy for advanced colorectal cancer an advantage for almost five months of survival, considerable efforts have been made to develop other angiogenesis-blocker. Subsequent buy Apatinib studies have attempted to comply with this advantage in other tumor types. Advanced gastrointestinal tumors are a variety of diseases, the prognosis depends h From the time of diagnosis. At one end of this spectrum is advanced gastric and pancreatic cancer, the consistently low survival rate are independent of diagnosis Ngig of treatment, at the other end of this spectrum is that metastatic colorectal cancer when used with a series treated by well-established therapies, erm a median survival time glicht over two years.
The use of biological agents, particularly antiangiogenic, has been at the forefront of clinical research in gastrointestinal tumors for most of the last ten years. The mechanical design of the underlying theories by inhibiting the formation of new blood vessels S, INCB018424 including improved delivery of additionally Tzlich administered cytostatic drugs and the F Promotion of the efficient supply of blood, and N intra hrstoffen intratumorally valid. Unfortunately for www.impactjournals.com / Oncotarget oncotarget 516 2010, 1: 515 529 uncertain reasons, many anti-angiogenic agents are not effective in gastrointestinal cancer.
Here we have the use of anti-angiogenesis compounds, the clinical benefits have to check in gastrointestinal tumors, discuss some new drugs currently under investigation, and draw critical conclusions about the effectiveness of this avenue as a cancer treatment in gastrointestinal tumors CANCER Sophagogastrischem feeder Lead cancer and Stomach cancer causes, the second and the sixth leading Krebsmortalit caused by t respectively. Adenocarcinoma Esophagus is now more common than squamous cell carcinoma in North America and Western Europe and, as it is often difficult to determine if the cancer comes from the gastro Sophagealen on ganges feeder Hre or distal to patients with advanced disease often treated used with advanced adenocarcinoma of the stomach. There are few data on the R The angiogenesis inhibitor in patients with carcinoma Epidemo Of feeder Lead cancer. As such, this discussion is limited adenocarcinoma of EGC. EGC patients with metastases survival rates 5 years 10 to 15%.
When compared to best supportive care, improving palliative cytotoxic chemotherapy survive. While there is no single internationally recognized standard of care system, the best survival rates were obtained with three combinations of drugs for doublet therapy. VEGF and angiogenesis appear to have an r In the pathogenesis and prognosis of EGC important. The expression of VEGF with increasing stage and the disease burden in the EGC. In addition, VEGF expression is a negative prognostic factor of survival for the patients in this group. In a stomach xenograft model, an inhibition of VEGF activity T by a neutralizing antibody Body immunoassay indicating effectively that the inhibition of VEGF have therapeutic value. The phase II trials of bevacizumab in combination with chemotherapy with docetaxel, cisplatin and FU showed promising results in patients previously treated and untreated. Phase III study, AVAGAST combined placebo or bevacizumab with capecitabine and cisplatin showed a significant impro